Adimab
Adimab, a leading biotechnology company headquartered in the United States, was founded in 2007 and has since established itself as a pioneer in the field of antibody discovery and development. With a strong operational presence in key regions across the US and Europe, Adimab focuses on providing innovative solutions for therapeutic antibody generation, utilising its proprietary platform to streamline the discovery process. The company’s core offerings include a robust suite of services that enable partners to develop high-quality monoclonal antibodies efficiently. Adimab's unique approach combines advanced technology with a deep understanding of immunology, positioning it as a trusted partner for pharmaceutical and biotechnology firms. Notable achievements include collaborations with major industry players, solidifying its reputation as a leader in the antibody discovery landscape.
DitchCarbon Score
How does Adimab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adimab's score of 13 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Adimab's reported carbon emissions
In 2019, Adimab reported total carbon emissions of approximately 394,000 kg CO2e, with emissions distributed across Scope 1 and Scope 2. Specifically, Scope 1 emissions were about 39,400 kg CO2e, while Scope 2 emissions also accounted for approximately 39,400 kg CO2e. Notably, there were no reported Scope 3 emissions, although waste generated in operations contributed significantly, amounting to about 493,000 kg CO2e. Currently, Adimab has not established any formal reduction targets or climate pledges, indicating a potential area for future commitment in addressing climate change. As a biotechnology company headquartered in the US, Adimab's emissions profile reflects its operational impact, and the absence of Scope 3 emissions suggests a focus on direct and indirect energy use rather than supply chain emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | |
|---|---|
| Scope 1 | 39,400 |
| Scope 2 | 39,400 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adimab is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
